Press releases

Regulatory

November 30, 2022

Vivesto announces that Christer Nordstedt will remain as acting CEO during a transition period

Regulatory

November 21, 2022

Vivesto appoints Erik Kinnman as CEO

Regulatory

November 21, 2022

Nomination Committee appointed for the 2023 Annual General Meeting in Vivesto

Regulatory

November 17, 2022

Interim report for the period January 1, 2022 – September 30, 2022

Regulatory

November 3, 2022

Christer Nordstedt resigns as acting CEO of Vivesto

Regulatory

August 25, 2022

Interim report for the period January 1, 2022 – June 30, 2022

Regulatory

July 21, 2022

Vivesto appoints Christer Nordstedt as acting CEO

Regulatory

July 5, 2022

Vivesto winds down its activities in Russia

Regulatory

June 30, 2022

Vivesto appoints Robert Maiorana as acting CFO

Regulatory

June 13, 2022

Vivesto and CEO Francois Martelet have agreed on ending the employment relationship

Regulatory

May 25, 2022

Report from Annual General Meeting in Vivesto AB

Regulatory

May 25, 2022

Interim report for the period January 1, 2022 – March 31, 2022

Regulatory

April 29, 2022

New number of shares and votes in Vivesto

Regulatory

April 28, 2022

Correction: Vivesto publishes Annual Report for 2021

Regulatory

April 28, 2022

Vivesto publishes Annual Report for 2021

Regulatory

April 25, 2022

Notice of Annual General Meeting in Vivesto AB

Regulatory

April 19, 2022

The Nomination Committee of Vivesto proposes election of new Board members and new Chairman of the Board

Regulatory

March 31, 2022

New number of shares and votes in Vivesto

Regulatory

March 25, 2022

FINAL RESULT OF OASMIA’S RIGHTS ISSUE

Regulatory

March 24, 2022

PRELIMINARY RESULT OF OASMIA’S RIGHTS ISSUE

Regulatory

March 3, 2022

Oasmia announces CFO Fredrik Järrsten to step down later this year

Regulatory

March 3, 2022

OASMIA PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE

Regulatory

February 24, 2022

Year-end report January 1, 2021 – December 31, 2021

Regulatory

February 21, 2022

Bulletin from Extraordinary General Meeting in Oasmia Pharmaceutical AB

Regulatory

January 19, 2022

Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB

Regulatory

January 19, 2022

Vivesto announces that Christer Nordstedt will remain as acting CEO during a transition period

Vivesto appoints Erik Kinnman as CEO

Nomination Committee appointed for the 2023 Annual General Meeting in Vivesto

Interim report for the period January 1, 2022 – September 30, 2022

Christer Nordstedt resigns as acting CEO of Vivesto

Interim report for the period January 1, 2022 – June 30, 2022

Vivesto appoints Christer Nordstedt as acting CEO

Vivesto winds down its activities in Russia

Vivesto appoints Robert Maiorana as acting CFO

Vivesto and CEO Francois Martelet have agreed on ending the employment relationship

Report from Annual General Meeting in Vivesto AB

Interim report for the period January 1, 2022 – March 31, 2022

New number of shares and votes in Vivesto

Correction: Vivesto publishes Annual Report for 2021

Vivesto publishes Annual Report for 2021

Notice of Annual General Meeting in Vivesto AB

The Nomination Committee of Vivesto proposes election of new Board members and new Chairman of the Board

New number of shares and votes in Vivesto

FINAL RESULT OF OASMIA’S RIGHTS ISSUE

PRELIMINARY RESULT OF OASMIA’S RIGHTS ISSUE

Oasmia announces CFO Fredrik Järrsten to step down later this year

OASMIA PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE

Year-end report January 1, 2021 – December 31, 2021

Bulletin from Extraordinary General Meeting in Oasmia Pharmaceutical AB

Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB

OASMIA RESOLVES ON A FULLY SECURED RIGHTS ISSUE OF APPROXIMATELY SEK 151 MILLION

Investor contact

IR@vivesto.com

+46 18-50 54 40